European Journal of Cancer
Volume 44, Issue 2 , Pages 216-223 , January 2008

An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer

  • P.M. Patel

      Affiliations

    • Academic Division of Clinical Oncology, University of Nottingham, Nottingham University Hospitals – City Campus, Nottingham NG51PB, UK
    • Corresponding Author InformationCorresponding author: Tel.: +44 1158238150; fax: +44 1158238149.
    • ,
  • S. Sim

      Affiliations

    • Cancer Research UK Clinical Centre, St. James’s University Hospital, Beckett Street, Leeds, UK
    • ,
  • D.O. O’Donnell

      Affiliations

    • Haematology Oncology Care Centre, St. James’s Hospital, Dublin 8, Ireland
    • ,
  • A. Protheroe

      Affiliations

    • Cancer Research UK, Department of Medical Oncology, Churchill Hospital, Oxford, United Kingdom
    • ,
  • D. Beirne

      Affiliations

    • Cancer Research UK Clinical Centre, St. James’s University Hospital, Beckett Street, Leeds, UK
    • ,
  • A. Stanley

      Affiliations

    • Cancer Research UK Clinical Centre, St. James’s University Hospital, Beckett Street, Leeds, UK
    • ,
  • J.M. Tourani

      Affiliations

    • Medical Oncology Unit, CHU de Poitiers, Poitiers, France
    • ,
  • D. Khayat

      Affiliations

    • Department of Medical Oncology, Salpetriere Hospital, Paris, France
    • ,
  • B. Hancock

      Affiliations

    • Yorkshire Cancer Research Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, United Kingdom
    • ,
  • P. Vasey

      Affiliations

    • University of Queensland, Division of Medicine, Brisbane, Australia
    • ,
  • A. Dalgleish

      Affiliations

    • Division of Oncology, St. George’s Hospital Medical School, London, UK
    • ,
  • C. Johnston

      Affiliations

    • Cancer Research UK Clinical Centre, St. James’s University Hospital, Beckett Street, Leeds, UK
    • ,
  • R.E. Banks

      Affiliations

    • Cancer Research UK Clinical Centre, St. James’s University Hospital, Beckett Street, Leeds, UK
    • ,
  • P.J. Selby

      Affiliations

    • Cancer Research UK Clinical Centre, St. James’s University Hospital, Beckett Street, Leeds, UK

Received 23 July 2007 ,Accepted 2 November 2007.

References 

  1. Linehan W, Shipley W, Parkinson D. Cancer of the kidney and ureter. In:  Devita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles and Practice of Oncology. PA, USA: Lippincott; 1993;p. 1023–1051
  2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. New Engl J Med. 1996;335:865–875
  3. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–2540
  4. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14–17
  5. Hancock B, Griffiths G, Ritchie A, et al. Proc Am Soc Clin Oncol. 2000;1336
  6. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859
  7. Baaten G, Voogd AC, Wagstaff J. A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer. Eur J Cancer. 2004;40:1127–1144
  8. Fisher R, Rosenberg S, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl. 1):S55–S57
  9. Geertsen P, Gore M, Negrier S, Tourani J, von der Maase H. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer. 2004;90:1156–1162
  10. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–3132
  11. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med. 2007;356:125–134
  12. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med. 2007;3(56):115–124
  13. Suppiah R, Finke J, Rini BI, et al. T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. J Clin Oncol [Meeting Abstracts]. 2006;24(18 Suppl.):2526
  14. Coley W. Treatment of inoperable malignant tumours with the toxins of erysipelas and the Bacillus prodigious. Trans Am Surg Assoc. 1894;12:183
  15. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 1994;39:93–98
  16. Townsend S, Allison J. Tumor rejection after direct costimulation of CD8+T cells by B7-transfected melanoma cells. Science. 1993;259:368–370
  17. Abou-Zeid C, Gares MP, Inwald J, et al. Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun. 1997;65:1856–1862
  18. Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology. 1998;93:307–313
  19. Dlugovitzky D, Bottasso O, Dominino JC, et al. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Resp Med. 1999;93:557–562
  20. Dlugovitzky D, Fiorenza G, Farroni M, Bogue C, Stanford C, Stanford J. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Resp Med. 2006;100:1079–1087
  21. Yamamura M, Modlin R, Ohmen J, Moy R. Local expression of antiinflammatory cytokines in cancer. J Clin Invest. 1993;93:1005–1010
  22. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). BJU Int. 1998;82:568–573
  23. Maraveyas AD, Baban B, Kennard D, et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol. 1999;10:817–824
  24. Nicholson S, Guile K, John J, et al. A randomized phase II trial of SRL172 (Mycobacterium vaccae)+/− low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res. 2003;13:89–93
  25. Assersohn L, Souberbielle BE, O’Brien MER, et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin Oncol. 2002;14(1):23–27
  26. Mendes R, Orme IM, Mitra A, et al. Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. Br J Cancer. 2002;6:336–341
  27. O’Brien M, Saini A, Smith I, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer. 2000;83:853–857
  28. Harper-Wynne CL, Sumpter K, Ryan C, et al. Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control. Lung Cancer. 2005;47:289–290
  29. O’Brien MER, Anderson H, Kaukel E, et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol. 2004;15:906–914
  30. Stanford J, Stanford C, O’Brien M, Grange J. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer. 2007;
  31. Fossa S, Jones M, Johnson P, et al. Interferon-alpha and survival in renal cell cancer. Br J Urol. 1995;76:286–290
  32. Jones M, Philip T, Palmer P, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother. 1993;8:275–288
  33. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–463
  34. Grange J, O’Brien M, Hobohm U, et al. The role and rationale of adjuvant-based agents including heat-killed Mycobacterium vaccae for the immunotherapy of cancer. Eur J Cancer. 2007;

PII: S0959-8049(07)00863-5

doi: 10.1016/j.ejca.2007.11.003

European Journal of Cancer
Volume 44, Issue 2 , Pages 216-223 , January 2008

Article Tools

* Image Usage & Resolution